

31
filed December 21, 1995, and PCT /US96/20577 filed on December 19, 1996, which are hereby incorporated herein by reference in their entirety.--

On page 6, line 23, after "GRGDSP", please insert --(SEQ ID NO: 2)--.

On page 6, line 23, after "SPGDRG", please insert--(SEQ ID NO:3)--.

On page 34, line 9, after "GRGDSP", please insert --(SEQ ID NO:2)--.

On page 34, line 25, after "SFGRGDIRN", please insert -- (SEQ ID NO: 4)--.

On page 37, line 24, after "GRGDSP", please insert --(SEQ ID NO: 2)--.

IN THE CLAIMS

Please amend the claims as follows:

2.1. A targeted therapeutic or diagnostic agent comprising (a) a therapeutic or diagnostic functional entity linked to (b) an isolated peptide mimetic which is based on an optimized [high affinity polyamino acid] protein surface loop and wherein the mimetic specifically binds a selected target.

3. A protein comprising a[n isolated naturally occurring or] grafted optimized protein surface loop that specifically binds a selected target, wherein the protein surface loop is not endogenous to the protein [and], replaces a surface loop on the protein, and is optimized prior to grafting.

33
Sub
C1

- 63
4. The targeted agent of [any of] claim[s] 1 [or 2], wherein the functional entity is a medical or diagnostic device.
 5. The targeted agent of [any of] claim[s] 1 [or 2], wherein the entity is a cell, virus, gene delivery vehicle or a biological molecule.
 6. The targeted agent of [any of] claim[s] 1 [or 2], wherein the entity is a synthetic or naturally occurring macromolecule.
 7. The targeted agent of [any of] claim[s] 1 [or 2], wherein the entity is a synthetic or naturally occurring peptide or protein.
 8. The targeted agent of [any of] claim[s] 1 [or 2], wherein the entity is a synthetic or naturally occurring enzyme.
 9. The targeted agent of [any of] claim[s] 1 [or 2], wherein the entity is a thrombolytic agent or an anticoagulant.
 10. The targeted agent of [any of] claim[s] 1 [or 2], wherein the entity is a plasminogen activator.
 11. The targeted agent of [any of] claim[s] 1 [or 2], wherein the entity is tissue type plasminogen activator (tPA), or a variant of tissue type plasminogen activator.
 12. The targeted agent of [any of] claim[s] 1 [or 2], wherein the entity is loop-grafted tissue type plasminogen activator (LG-tPA).

13. The targeted agent or protein of any of claims 1 or [2] 3, wherein the target is a biological entity.
14. The targeted agent or protein of any of claims 1 or [2] 3, wherein the target is an organ, tumor, tissue, cell, virus, or microorganism.
15. The targeted agent or protein of any of claims 1 or [2] 3, wherein the target is a synthetic or naturally occurring macromolecule.
16. The targeted agent or protein of any of claims 1 or [2] 3, wherein the target is a protein.
17. The targeted agent or protein of any of claims 1 or [2] 3, wherein the target is a cell surface protein.
18. The targeted agent or protein of any of claims 1 or [2] 3, wherein the target is an integrin.
19. The targeted agent or protein of any of claims 1 or [2] 3, wherein the target is an integrin that binds to an Arg-Gly-Asp (RGD) tripeptide motif.
20. The targeted agent or protein of any of claims 1 or [2] 3, wherein the target is $\alpha_{IIb}\beta_3$ integrin.
21. The targeted agent or protein of any of claims 1 or [2] 3, wherein the target is $\alpha_v\beta_3$ integrin.
22. The targeted agent or protein of any of claims 1 or [2] 3, wherein the optimized, [high affinity polyamino acid] protein surface loop is a complementarity determining region of an IgG-like molecule.